

Jianyang Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2042541/publications.pdf>

Version: 2024-02-01

26
papers

239
citations

1307594

7
h-index

1125743

13
g-index

31
all docs

31
docs citations

31
times ranked

310
citing authors

#	ARTICLE	IF	CITATIONS
1	Epithelial circulating tumor cells with a heterogeneous phenotype are associated with metastasis in NSCLC. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1137-1146.	2.5	12
2	Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 810580.	2.8	0
3	Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492210803.	1.3	2
4	Chemoradiotherapy is an alternative choice for patients with primary mediastinal seminoma. <i>Radiation Oncology</i> , 2022, 17, 58.	2.7	4
5	Development and validation of a prediction model using molecular marker for long-term survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy. <i>Thoracic Cancer</i> , 2022, 13, 296-307.	1.9	4
6	The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patients. <i>Molecular Cancer</i> , 2022, 21, 117.	19.2	15
7	A validation study on the lung immune prognostic index for prognostic value in patients with locally advanced non-small cell lung cancer. <i>Radiation Oncology</i> , 2021, 156, 244-250.	0.6	7
8	Risk of cardiac-related mortality in stage IIIA-N2 non-small cell lung cancer: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database. <i>Thoracic Cancer</i> , 2021, 12, 1358-1365.	1.9	6
9	Clinical outcomes and radiation pneumonitis after concurrent EGFR tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 814-823.	1.9	17
10	MIR-320b/RAD21 axis affects hepatocellular carcinoma radiosensitivity to ionizing radiation treatment through DNA damage repair signaling. <i>Cancer Science</i> , 2021, 112, 575-588.	3.9	31
11	Additional Radiotherapy With or Without Chemotherapy Following Endoscopic Resection for Stage I Esophageal Carcinoma: A Pilot Study. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110480.	1.9	5
12	Endostar (rhendostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis. <i>Thoracic Cancer</i> , 2021, 12, 3208-3215.	1.9	9
13	Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases. <i>Thoracic Cancer</i> , 2021, 12, 3407-3415.	1.9	14
14	A Nomogram for Predicting Brain Metastasis in IIIA-N2 Non-Small Cell Lung Cancer After Complete Resection: A Competing Risk Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 781340.	2.8	4
15	Locoregional recurrence patterns in women with breast cancer who have not undergone post-mastectomy radiotherapy. <i>Radiation Oncology</i> , 2020, 15, 212.	2.7	4
16	A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol. <i>BMC Cancer</i> , 2020, 20, 901.	2.6	7
17	S-1-Based Chemoradiotherapy Followed by Consolidation Chemotherapy With S-1 in Elderly Patients With Esophageal Squamous Cell Carcinoma: A Multicenter Phase II Trial. <i>Frontiers in Oncology</i> , 2020, 10, 1499.	2.8	9
18	Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non-small cell lung cancer: Chinese multicenter report and literature review. <i>Thoracic Cancer</i> , 2020, 11, 2916-2923.	1.9	7

#	ARTICLE	IF	CITATIONS
19	Development and external validation of a nomogram to predict four or more positive nodes in breast cancer patients with one to three positive sentinel lymph nodes. <i>Breast</i> , 2020, 53, 143-151.	2.2	9
20	Evaluation of Privacy Risks of Patients' Data in China: Case Study. <i>JMIR Medical Informatics</i> , 2020, 8, e13046.	2.6	10
21	Tumor Mutation Load: A Novel Independent Prognostic Factor in Stage IIIA-N2 Non-Small-Cell Lung Cancer. <i>Disease Markers</i> , 2019, 2019, 1-10.	1.3	7
22	Comparison of Treatment Outcomes With Breast-conserving Surgery Plus Radiotherapy Versus Mastectomy for Patients With Stage I Breast Cancer: A Propensity Score-matched Analysis. <i>Clinical Breast Cancer</i> , 2018, 18, e975-e984.	2.4	21
23	Role of radiotherapy in treating patients with primary malignant mediastinal non-seminomatous germ cell tumor: A 21-year experience at a single institution. <i>Thoracic Cancer</i> , 2015, 6, 399-406.	1.9	21
24	Postoperative intensity-modulated radiation therapy provides favorable local control and low toxicities in patients with soft tissue sarcomas in the extremities and trunk wall. <i>OncoTargets and Therapy</i> , 2015, 8, 2843.	2.0	8
25	Malignant thrombosis of the superior vena cava caused by non-small-cell lung cancer treated with radiation and erlotinib: a case with complete and prolonged response over 3 years. <i>OncoTargets and Therapy</i> , 2013, 6, 749.	2.0	2
26	High-sensitive C-reactive protein predicts outcome after coronary artery bypass. <i>Asian Cardiovascular and Thoracic Annals</i> , 2012, 20, 525-533.	0.5	3